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Summary
Background: The lateral segregation of Ras proteins into
transient plasma membrane nanoclusters is essential for
high-fidelity signal transmission by the Ras mitogen-activated
protein kinase (MAPK) cascade. In this spatially constrained
signaling system, the dynamics of Ras nanocluster assembly
and disassembly control MAPK signal output.
Results: We show here that BRaf inhibitors paradoxically
activate CRaf and MAPK signaling in Ras transformed cells
by profoundly dysregulating Ras nanocluster dynamics.
Specifically, BRaf inhibitors selectively enhance the plasma
membrane nanoclustering of oncogenic K-Ras and N-Ras
but have no effect on H-Ras nanoclustering. Raf inhibitors
are known to drive the formation of stable BRaf-CRaf and
CRaf-CRaf dimers. Our results demonstrate that the presence
of two Ras-binding domains in a single Raf dimer is sufficient
and required to increase Ras nanoclustering, indicating that
Raf dimers promote K- and N-Ras nanocluster formation by
crosslinking constituent Ras proteins. Ras crosslinking
increases the fraction of K-Ras and N-Ras in their cognate
nanoclusters, leading to an increase in MAPK output from
the plasma membrane. Intriguingly, increased MAPK signal-
ing in BRaf inhibited cells is accompanied by significantly
decreased Akt activation. We show that this signal pathway
crosstalk results from a novel mechanism of competition
between stabilized Raf dimers and p110a for recruitment to
Ras nanoclusters.
Conclusions: Our findings reveal that BRaf inhibitors disrupt
Ras nanocluster dynamics with significant, yet divergent,
consequences for MAPK and PI3K signaling.Introduction
The plasma membrane is a dynamic, laterally heterogeneous
structure that confers nonrandom spatial distributions on
proteins in different types of transient yet functional nanoscale
domains [1–5]. Understanding the underlying mechanisms
that govern plasma membrane nanostructure is important
because critical emergent properties can result from the*Correspondence: richard.marais@icr.ac.uk (R.M.), john.f.hancock@uth.
tmc.edu (J.F.H.)spatial organization of signaling molecules. For example, the
spatial organization of Ras proteins into plasma membrane
nanoclusters is essential for high-fidelity signal transmission
by the Ras-MAPK (mitogen-activated protein kinase) cascade
[3, 6–8]. Ras guanosine triphosphate (GTP) nanoclusters are
small (<20 nm in diameter), containw7 Ras proteins, and are
the exclusive sites of Raf recruitment and ERK activation on
the plasma membrane [3, 6, 8]. Raf activation within, and
MAPK output from, an active Ras nanocluster is limited by
the short (<1 s) lifetime of the cluster because disassembly
of the nanocluster terminates signal output [3, 7, 8]. In this
spatially constrained signaling system, the fraction of Ras
proteins that assemble into nanoclusters and the lifetime of
the nanocluster become important system parameters that
determine MAPK responsiveness [3, 6–8]. Assessment of the
importance of these system parameters has been limited to
MAPK activation in model experimental cell systems, and the
possible broader implications of modulating Ras nanocluster-
ing has not been examined.
The discovery of BRaf as a frequent target for mutation in
human tumors has driven the development of BRaf kinase
inhibitors that have had marked clinical success in tumors
such as melanoma [9–11]. In cells transformed by oncogenic
mutant BRafV600E, ATP-competitive BRaf inhibitors abrogate
ERK activation; however, in cells transformed by oncogenic
mutant K- or N-Ras, these same inhibitors drive paradoxical
MAPK activation in a CRaf-dependent manner [12–14]. Block-
ing BRaf activity using chemical inhibitors, or by mutation,
drives kinase domain dimerization with CRaf and is permissive
for CRaf activation [12, 13]. CRaf homodimerization is also
promoted if the inhibitor binds to one CRaf protein in the
dimer, to permit transactivation of the nonliganded CRaf
protein [14]. Raf dimerization is essential for activation of the
MAPK cascade because point mutations, which block Raf
dimerization, prevent inhibitor-induced ERK activation
[13, 14]. In cells expressing oncogenic Ras, BRaf inhibitors
induce enhanced Ras-dependent translocation of wild-type
(WT) BRaf and CRaf to the plasma membrane [12, 13].
Enhanced plasmamembrane localization of CRaf in turn corre-
lates closely with CRaf and MAPK activation [12–14]. Taken
together, these studies clearly demonstrate that Ras is
required to translate BRaf-CRaf or CRaf-CRaf dimerization
into MAPK activation in intact cells, but the molecular role of
Ras on the plasma membrane has not been elucidated.
In this study we examined whether Raf inhibitors perturb
Ras spatiotemporal dynamics and show for the first time that
induced changes to the emergent properties of Ras nanoclus-
ters fully account for the observed effects of Raf inhibitors on
Ras signal transmission.
Results
Raf Inhibition Stimulates Oncogenic K-Ras and N-Ras
Nanoclustering on the Plasma Membrane
Several studies have reported that treatment of oncogenic
mutant Ras transformed cells with BRaf inhibitors significantly
enhances the plasma membrane recruitment of CRaf [12, 13,
15]. BecauseRas.GTP nanoclusters are the sites of Raf recruit-
ment to the plasma membrane [3, 6, 8], these observations
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Figure 1. Raf Inhibition Enhances Oncogenic K-Ras and N-Ras Nanoclustering
(A, D, and G) BHK cells expressingmGFP- andmRFP-RasG12V were treated with Raf inhibitors (0.1 mMSB590885, 10 mM sorafenib) for 4 hr, and the lifetime
of GFP measured using a FLIM-microscope. The graph shows mean fluorescence lifetime of GFP 6 SEM (n R 102 cells, from three independent
experiments). Significant differences between Raf inhibitor-treated and control (DMSO-treated) cells were assessed using one-way ANOVA tests
(***p < 0.001).
(C, F, and I) Representative pseudocolored images showing average GFP fluorescence lifetime (tav) in nanoseconds and the mGFP-RasG12V FRET
fraction (a). The image labeled GFP is from cells expressing mGFP-RasG12V only; the other images are from cells coexpressing mGFP- and
mRFP-RasG12V. Treatment with Raf inhibitors had no effect on mGFP-RasG12V lifetime in cells not expressing a FRET acceptor (Figure S1).
(B, E, andH) Intact plasmamembrane sheets prepared fromBHK cells expressingmGFP-RasG12V and treated for 4 hr with Raf inhibitors (0.1 mMSB590885,
10 mMsorafenib) were immunogold labeled. Spatial mapping of the gold-labeledRas distribution was performed for each experimental condition. The L(r) – r
curve is a weighted mean K function (n R 15), where values above the 99% C.I. for a random pattern indicate clustering at that value of r. Significant
differences between the L(r) – r curves of Raf inhibitor-treated and control (DMSO treated) cells were evaluated in bootstrap tests (***p < 0.001). Sample
micrographs are shown in Figure S1.
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946strongly suggested that BRaf inhibitors might increase the
fraction of oncogenic Ras proteins that assemble into
nanoclusters. To examine the effect of blocking Raf kinase
activity on Ras nanoclustering, we treated baby hamster
kidney (BHK) cells transiently coexpressing mGFP- and
mRFP-tagged oncogenic K-RasG12V (KG12V) with the BRaf
inhibitor SB590885 or the BRaf and CRaf inhibitor sorafenib
[16, 17]. Nanoclustering was assayed by measuring mGFP
fluorescence lifetime using a fluorescence-lifetime imaging
microscopy (FLIM) microscope. In untreated control cells, co-
expression of mGFP-KG12V and mRFP-KG12V significantly
decreased mGFP fluorescence lifetime, indicating fluores-
cence resonance energy transfer (FRET) between mGFP-
KG12V and mRFP-KG12V molecules. This result is consistent
with previous results showing that a fraction (w40%) of
KG12V proteins are arrayed in nanoclusters on the plasmamembrane [3, 8]. Treatment with SB590885 or sorafenib
induced further reductions in mGFP-KG12V fluorescence life-
time (Figures 1A and 1C). These reductions in mGFP fluores-
cence lifetime were a consequence of a substantial increase
in the fraction of mGFP-KG12V molecules undergoing FRET
in the BRaf inhibited cells (see Table S1A available online).
These results indicate that Raf inhibition significantly increases
KG12V nanoclustering. To validate this conclusion, we pre-
pared intact 2D plasma membrane sheets from BHK cells ex-
pressing mGFP-KG12V and labeled with anti-GFP antibody
conjugated directly to 5 nm gold particles. Images of the gold
particles were taken using an electron microscope (EM) and
the spatial organization of mGFP-KG12V was analyzed using
Ripley’s K-function (Figure 1B). The L(r) – r plots show that
mGFP-KG12V is clustered in control cells but that mGFP-
KG12V clustering is significantly increased when cells are
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Figure 2. Kinase-Dead BRaf Enhances Oncogenic K-Ras and N-Ras Nanoclustering
(A, D, and G) BHK cells were cotransfected with BRaf constructs in the presence of mGFP- and mRFP- RasG12V, and the fluorescence lifetime of GFP
measured using a FLIM-microscope. The graph showsmean fluorescence lifetime of GFP6 SEM (nR 95 cells, from three independent experiments). Signif-
icant differences between BRaf-transfected and empty vector-transfected cells were assessed using one-way ANOVA tests (***p < 0.001).
(C, F, and I) Representative pseudocolored images showing average GFP fluorescence lifetime (tav) in nanoseconds and the mGFP-RasG12V FRET fraction
(a). The image labeled GFP is from cells expressing mGFP-RasG12V only; the other images are from cells coexpressing mGFP- and mRFP-RasG12V.
(B, E, and H) Intact plasma membrane sheets were prepared from BHK cells expressing mGFP-RasG12V and BRaf constructs and immunogold labeled.
Spatial mapping of the gold-labeled Ras distribution was performed for each experimental condition. The L(r) – r curve is a weighted mean K-function
(n R 15), where values above the 99% C.I. for a random pattern indicate clustering at that value of r. Significant differences between the L(r) – r curves
of BRaf-transfected and empty vector-transfected cells were evaluated in bootstrap tests (***p < 0.001).
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947treated with sorafenib or SB590885. Further interrogation
of these spatial point patterns showed that the increase in
L(r) – r values is accounted for by an increase in the mGFP-
KG12V clustered fraction (Table S1A). Because the ability of
different Ras isoforms to recruit Raf proteins to nanoclusters
varies, we repeated these experiments with cells transformed
by oncogenic N-RasG12V (NG12V) or oncogenic H-RasG12V
(HG12V). The results show that SB590885 and sorafenib treat-
ment significantly increased NG12V nanoclustering (Figures
1D–1F; Table S1B) but had no effect on HG12V nanoclustering
(Figures 1G–1I; Table S1C).
Ectopic expression of kinase-dead BRaf in Ras transformed
cells enhances MAPK activation as efficiently as treatment
with SB590885 [12]. We therefore analyzed Ras spatial organi-
zation in cells coexpressing BRaf mutants. The FLIM-FRET
and EM analyses in Figures 2A–2F show that ectopic expres-
sion of kinase-dead BRaf (D594A), but not WT or constitutively
active BRaf (V600E), significantly increased KG12V and NG12V
nanoclustering but had no effect on HG12V nanoclustering
(Figures 2G–2I). These results are consistent with previouswork showing that membrane-recruited CRaf is efficiently
retained in KG12V but not HG12V nanoclusters [18]. Taken
together, the data in Figures 1 and 2 and Table S1 show that
BRaf inhibition significantly increases the nanoclustering of
oncogenic K- and N-Ras on the plasma membrane.
Ras-Binding Domains of B- and C-Raf Are Sufficient for
Stimulating Oncogenic K-Ras and N-Ras Nanoclustering
The crosslinking of lipid raft domains by multivalent ligands or
antibodies can stabilize these transient nanodomains and acti-
vate associated signaling complexes [19, 20]. We reasoned
that a similar mechanism could operate in cells treated with
BRaf inhibitors because the formation of stable CRaf-BRaf or
CRaf-CRaf dimers [12–14], which have two Ras binding
domains (RBDs), could potentially crosslink nanoclustered
Ras proteins. We therefore generated a tandem RBD-CRD
fusion protein (23RBD-CRD) comprising the RBD and
cysteine-rich domain (CRD) of BRaf and CRaf (Figure 3A)
separated by a short flexible linker sequence. As a control,
we introduced a point mutation at a critical arginine residue
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Figure 3. A Dimer of the RBD of CRaf and BRaf Is Sufficient to Enhance K-Ras and N-Ras Nanoclustering
(A) Diagram of the tandem RBD-CRD construct (23RBD-CRD), comprising amino acids 150–300 of BRaf and amino acids 2–200 of CRaf joined by poly-Gly
linker and appended with an N-terminal hemagglutinin epitope tag (HA). The 23RBD*-CRD contains a R188G point mutation in the BRaf RBD sequence,
which abrogates Ras binding.
(B, E, and H) BHK cells were cotransfected with tandem RBD-CRD constructs in the presence of mGFP- andmRFP-RasG12V, and the fluorescence lifetime
of GFP was measured using a FLIM microscope. The graph shows mean fluorescence lifetime of GFP 6 SEM (n R 92 cells, from three independent
experiments). Significant differences between cells expressing tandemRBD-CRD constructs and empty vector were assessed using one-way ANOVA tests
(***p < 0.001).
(D, G, and J) Representative pseudocolored images showing averageGFP fluorescence lifetime (tav) in nanoseconds and themGFP-RasG12V FRET fraction
(a). The image labeled GFP is from cells expressing mGFP-RasG12V only; the other images are from cells coexpressing mGFP- and mRFP-RasG12V.
(C, F, and I) Intact plasmamembrane sheets were prepared fromBHK cells expressingmGFP-RasG12V and tandemRBD-CRD constructs and immunogold
labeled. Spatial mapping of the gold-labeled Ras distribution was performed for each experimental condition. The L(r) – r curve is a weighted mean K-func-
tion (nR 15), where values above the 99%C.I. for a random pattern indicate clustering at that value of r. Significant differences between the L(r) – r curves of
tandem RBD-CRD constructs and empty vector-transfected cells were evaluated in bootstrap tests (***p < 0.001 or **p < 0.01). See also Figure S2.
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948in the BRaf RBD (23RBD*-CRD), which abrogates Ras binding
[21]. FLIM-FRET imaging and EM spatial analysis showed that
ectopic expression of 23RBD-CRD, but not 23RBD*-CRD,
significantly increased the nanoclustering of KG12V and
NG12V (Figures 3B–3G; Tables S1A and S1B). Ectopic expres-
sion of 23RBD-CRD had no effect on the extent of HG12V
nanoclustering (Figures 3H–3J; Table S1C), consistent with
the results in Figures 1 and 2. We generated additional tandem
RBD-CRD fusion proteins to simulate CRaf-CRaf and BRaf-
BRaf homodimers; both of these homodimeric Raf fusionproteins increased the nanoclustering of NG12V and KG12V
but had no effect on HG12V nanoclustering (Figure S3). As
with the 23RBD*-CRD construct, a point mutation in a single
RBD abolished the ability of the homodimeric Raf fusion
proteins to increase Ras nanoclustering (Figure S3). Taken
together, these data indicate that two RBDs must be simulta-
neously available in a single Raf homo- or heterodimer to
enhance K-Ras.GTP or N-Ras.GTP nanoclustering and
suggest that crosslinking Ras.GTP proteins is the underlying
molecular mechanism that stabilizes Ras nanoclusters.
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Figure 4. BRaf Inhibition Activates ERK but Reduces Akt Phosphorylation
BHK cells stably expressing oncogenic Ras isoforms were treated with Raf
inhibitors (0.1 mMSB590885, 10 mMsorafenib) for 4 hr, and cell lysates immu-
noblotted for ppERKandpAkt (S473). The graphs showmean ppERK (A) and
mean pAkt levels6 SEM (n = 3) (B) relative to the respective control (DMSO-
treated) treated RasG12V cell line. (Con, control [DMSO]; SB, SB590885;
and SF, sorafenib). Significant differences between control and Raf inhib-
itor-treated cells were assessed using one-way ANOVA tests (**p < 0.01 or
*p < 0.05). A representative blot is shown (C) (Con, control [DMSO]; SB,
SB590885; and SF, sorafenib). Serum starved BHK cells stably expressing
oncogenic Ras isoforms were treated for 2 hr with SB590885. Cell lysates
were immunoblotted for ppERK and pAkt(S473). The graphs show mean
ppERK (D), and mean pAkt levels 6 SEM (n = 3) (E) relative to respective
control RasG12V cells lines. A representative blot is shown in Figure S3.
Untransfected serum starved BHK cells were pretreated for 2 hr with Raf
inhibitors (0.1 mM SB590885, 50 mM sorafenib) and stimulated for 2 min
with EGF. Cell lysates were immunoblotted for ppERK and pAkt(S473). The
graphs show mean ppERK (F), and mean pAkt levels 6 SEM (n = 3) (G).
A representative blot is shown in Figure S3.
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949Table S1 also shows that treatment with BRaf inhibitors or
expression of kinase-dead BRaf (D594A) or 23RBD-CRD,
while not increasing the average number of Ras molecules
per cluster, all increase FRET efficiency, suggesting that orga-
nization of K-Ras and N-Ras proteins within their cognate
nanoclusters is altered as a result of Ras crosslinking.
Given the selective effect of BRaf inhibitors on the clustering
of N- and K-Ras, we looked for isoform selective effects on
signal transmission. BHK cells stably expressing oncogenic
K-, N-, or H-Ras were treated with Raf inhibitors and ppERK
and pAkt (S473) levels were measured. SB590885 induced
significantly greater ERK activation in KG12V and NG12V cells
than in HG12V cells (Figure 4A). Interestingly SB590885 also
significantly reduced Akt phosphorylation in all three trans-
formed cell lines (Figure 4B). The effects of SB590885 on
stimulating activation of ERK and inhibiting activation of Akt
in cells stably expressing oncogenic K-, N-, or H-Ras were
dose-dependent (Figures 4D and 4E; Figures S3A and S3B).
Sorafenib treatment had no detectable effect on ppERK levels
in the KG12V, NG12V, and HG12V cells, unless used at high
concentrations (Figure S3E), but as seen with SB590885, sor-
afenib significantly inhibited pAkt levels in all three Ras trans-
formed cell lines. Similar effects of the Raf inhibitors were seen
on a cohort of six human endometrial, lung, and breast cancer
cell lines: SB590885, but not sorafenib, significantly stimulated
ppERK level in all cancer cell lines tested (Figures S3F–S3I),
with reciprocal inhibition of pAkt levels that was most marked
in cells expressing oncogenic K-Ras (HEC-1a, A549, andMDA-
MB-231) or constitutively active PI3K (ESS-1).
Endogenous Ras Signaling Is Dysregulated by Raf
Inhibitors
The spatiotemporal dynamics of Ras nanoclustering are criti-
cally important for high-fidelity signal transmission through
the MAPK cascade. Our computational experiments indicate
that increasing the fraction of Ras proteins that assemble
into clusters increases the gain in the EGF-MAPK signaling
pathway [3, 6, 7, 22, 23]. To assay for this effect, we preincu-
bated BHK cells with SB590885 or sorafenib and stimulated
for 2 min with nonsaturating doses of EGF. Stimulation times
were kept short so that only plasma membrane signaling
events were assayed [24–26] (Figures 4F and 4G; Figures
S3C and S3D). Control cells and cells pretreated with
SB590885 and sorafenib all showed linear ppERK dose
responses to low dose EGF stimulation; however, the slope
and magnitude of the ppERK response was substantially
greater in SB590885-treated cells, consistent with increased
signal gain. Sorafenib-treated cells showed a diminished
EGF response presumably because concomitant blockade
of CRaf kinase activity mitigates the potential enhanced
ppERK activation flowing from enhanced nanoclustering (Fig-
ure 4F). Of note, however, both Raf inhibitors significantly
reduced Akt phosphorylation in response to EGF stimulation
(Figure 4G), as seen in cells transformed by oncogenic
mutant Ras.
Competition for Stabilized Ras Nanoclusters between Raf
Dimers and PI3K
We consistently observed reduced Akt activation in cells
treated with Raf inhibitors, suggesting molecular competition
between dimerized Raf and PI3K for recruitment to Ras nano-
clusters. To explore this mechanism, we treated BHK cells
coexpressing RasG12V and BRaf or CRaf with Raf inhibitors
and measured Ras-Raf interactions in intact cells using
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Figure 5. Competition for Stabilized Nanoclusters between Raf and PI3K
BHK cells expressingmGFP-CRaf or mGFP-p110awith mRFP-RasG12Vwere treatedwith Raf inhibitors (0.1 mMSB590885, 10 mMsorafenib) for 4 hr, and the
fluorescence lifetime of GFP was measured in a FLIM microscope (A–C, E, and F). The graph shows mean fluorescence lifetime of GFP6 SEM (nR 50 cells,
from three independent experiments). Significant differences between Raf inhibitor-treated and DMSO-treated cells were assessed using one-way ANOVA
tests (***p < 0.001, **p < 0.01). BHK cells stably expressing mGFP-KG12V were treated with fendiline for 2 days and further incubated with Raf inhibitors
(0.1 mMSB590885, 10 mMsorafenib) for 4 hr. Cell lysateswere immunoblotted for CRaf-pS338, a phosphorylation site that correlateswith Raf activity. A repre-
sentative blot of three independent experiments is shown (D) (CON, DMSO treated control; SB, SB590885; andSF, sorafenib). Intact plasmamembrane sheets
wereprepared fromK-RasG12V transformedCHOcells expressingmGFP-p110a andmRFP-CRaf and immunogold labeledwith 6 nmanti-GFP and2 nmanti-
RFP gold. (G) Spatial analysis was performed using a bivariate K-function that determines whether one gold population is clustered with respect to the other.
TheLbiv (r) – rcurve isaweightedmeanbivariateK-function (n=25),wherevaluesabove the95%C.I. fora randompattern indicatecoclusteringat that valueof r.
Intact plasma membrane sheetes prepared from K-RasG12V transformed CHO cells expressing mGFP-p110a (H) or mRFP–CRaf (J) and treated with Raf
inhibitors (0.1 mM SB590885, 10 mM sorafenib) for 4 hr were immunogold labeled as in (G). Plasma membrane recruitment was assayed by counting gold
particles: the graph shows the mean number of gold particles/mm2 6 SEM (n R 25). Significant differences between Raf inhibitor-treated and control
(DMSO-treated) cells were assessed using one-way ANOVA tests (***p < 0.001, **p < 0.01, or *p < 0.05). The individual gold distributions corresponding
to mGFP-p110a (I) or mRFP–CRaf (K) were analyzed by univariate K-functions. Significant differences between Raf inhibitor-treated and control (DMSO-
treated) L (r) – r curves were evaluated in bootstrap tests (***p < 0.001). See also Figure S4.
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950FLIM-FRET imaging. The results show that the interactions of
BRaf and CRaf with KG12V, NG12V, and HG12V were all
increased in the presence of Raf inhibitors (Figures 5A–5C;
Figures S4A–S4C). The increased interaction of Raf dimers
with stabilized KG12V nanoclusters directly increases CRaf
activation, as evidenced by significantly enhanced CRaf
S338 phosphorylation in KG12V cells treated with sorafenib
or SB590885 (Figure 5D). Cotreating cells with fendiline, whichinhibits the plasmamembrane interaction of K-Ras (J.F.H. and
D.v.d.H., unpublished data), reversed CRaf activation by
SB590885 or sorafenib (Figure 5D). Thus K-Ras must be
localized specifically to the plasma membrane in order for
dimerized Raf to undergo activation.
Next, BHK cells were cotransfected with mGFP-p110a and
mRFP-KG12V or mRFP-HG12V, and mGFP fluorescence life-
time was used as a measure of RasG12V/p110a proximity.
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951FRET between mGFP-p110a and both mRFP-KG12V and
mRFP-HG12V was significantly reduced when cells were
treated Raf inhibitors (Figures 5E and 5F), suggesting that
p110a interaction with KG12V and HG12V is indeed abrogated
when Ras nanoclusters recruit BRaf-CRaf dimers. To confirm
this interpretation, we used EM to spatially map p110a and
CRaf distributions on the plasma membrane in the presence
and absence of Raf inhibitors. Intact 2D plasma membrane
sheets prepared from KG12V transformed Chinese hamster
ovarian (CHO) cells coexpressing mGFP-p110a and mRFP-
CRaf, were labeled with anti-GFP and anti-RFP antibodies
conjugated directly to 6 or 2 nm gold particles, respectively.
EM images of the gold particles were analyzed. The bivariate
K-function, Lbiv(r) – r, shows that mGFP-p110a and mRFP-
CRaf do not cocluster (Figure 5G), definitive evidence that
CRaf and PI3K proteins are not recruited to the same KG12V
nanoclusters. Treatment with BRaf inhibitors however simulta-
neously reduced p110a levels and increased CRaf levels on
the plasmamembrane as evidenced by the reciprocal changes
in labeling by 6 nm and 2 nm gold particles (Figures 5H and 5I).
Univariate K-function analysis, L(r) – r, of the individual gold
populations showed that p110a and CRaf proteins were both
recruited to plasma membrane nanoclusters, but whereas
the extent of p110a clustering did not change, the extent of
CRaf clustering significantly increased on treatment with
BRaf inhibitors (Figures 5J and 5K). These changes in clus-
tering are not a consequence of different gold pattern densi-
ties, because the spatial analysis corrects for this parameter.
Rather, taken together, the results show that when K-Ras.GTP
(KG12V) nanoclusters are crosslinked by BRaf-CRaf dimers,
the dimers are retained within the nanoclusters leading to
increased Raf levels and increased Raf clustering. In conse-
quence, fewer K-Ras.GTP (KG12V) nanoclusters are available
for p110a recruitment and activation. This mechanism fully
accounts for the reciprocal effects onMAPK andAkt activation
in cells treated with BRaf inhibitors. Finally, we determined
whether 23RBD-CRD molecules, in contrast to p110a, could
efficiently compete with signaling competent Raf dimers for
access to Ras nanoclusters. Figures S4D and S4E show that
KG12V nanoclustering in cells expressing 23RBD-CRD was
not further increased on treatment with SB90885; however,
23RBD-CRD significantly reduced SB590885-stimulated
MAPK activation in RasG12V cells.
BRaf Inhibition Increases the Probability of K-Ras
Nanocluster Formation
We have shown that BRaf inhibitors increase the fraction of
K-Ras and N-Ras in nanoclusters on the plasma membrane.
To explore the effect of Raf inhibitors on nanocluster
dynamics, we used single fluorophore video tracking (SFVT).
The diffusion of single Ras molecules on the plasma mem-
brane is characterized by periods of free diffusion interspersed
with periods of transient immobilization [27]; these transient
immobilization periods (TIMPs) correlate with assembly of
the Ras protein into a transient nanocluster [27, 28]. We there-
fore recorded and analyzed multiple trajectories of single
mGFP-KG12V molecules expressed in BHK cells in the pres-
ence of SB590885, sorafenib, or dimethyl sulfoxide (DMSO)
(control). Sample trajectory tracings are shown in Figure 6A,
and representative movies of the trajectories are included in
the Supplemental Information (Movies S1, S2, and S3). TIMP
durations and the radii of confinement of the TIMPs were
measured and are plotted as frequency histograms in Fig-
ure 6B. The radius of the TIMPs in these trajectories is similarto the radius of nanoclusters identified by EM, although the
accuracies of the determined radii are quite limited due to
the localization error of single fluorescent molecules (Figures
6B and 6C; Figure 1). The distributions of TIMP durations
were fitted by single exponential decay functions to estimate
decay constants (Figure 6B), which were corrected for the
photobleaching lifetime of mGFP on the cell surface (Fig-
ure 6C). The summary results show that the overall time frac-
tion of temporary immobilization of mGFP-KG12V increased
significantly when cells were treated SB590885 or sorafenib
(Figure 6C). This result qualitatively recapitulates the EM and
FLIM results in Figure 1 that showed an increase in the Ras
nanoclustered fraction. However, because SVFT tracking can
only identify Ras interactions with nanoclusters that have a
lifetime of >100 ms, we expect a higher clustered fraction
estimate from EM and FLIM imaging that identifies all Ras
nanoclusters (Table S1). Most interestingly, further analysis
of the SFVT data showed that the significant increase in the
time fraction of temporary immobilization is not due to a
change in the average lifetime of the TIMPs but rather a
reduced diffusing period between TIMPs, indicating an
increase in TIMP frequency (Figure 6C). Taking the results
together, we can conclude that BRaf inhibitor-induced Raf
dimers cause an increase in the rate, or probability, of Ras
nanocluster formation but do not actually prolong the lifetime
of Ras nanoclusters once they are assembled.
Discussion
Here we identify perturbation of Ras spatiotemporal dynamics
as the mechanistic basis of paradoxical activation of the
MAPK cascade by BRaf inhibitors [12–14, 29]. Specifically,
we show that Raf heterodimerization induced byRaf inhibitors,
or expression of kinase-dead BRaf, enhances the nanocluster-
ing of oncogenic K-Ras and N-Ras, but not H-Ras. These
effects are not limited to oncogenic Ras, because the nano-
clustering of, and MAPK signal output from, WT Ras.GTP is
also enhanced by BRaf inhibitors. Similar effects on oncogenic
mutant Ras.GTP and WT Ras.GTP nanoclusters is to be ex-
pected because the assembly and disassembly of signaling
Ras.GTP nanoclusters occur on a time scale of <1 s and is
not linked to GTP hydrolysis [27, 28].
Our results show that two Raf RBDsmust be simultaneously
available in a single dimer to bind to Ras.GTP in order to
enhance K-Ras.GTP and N-Ras.GTP nanoclustering. All Raf
dimers tested—BRaf-BRaf, CRaf-CRaf, and BRaf-CRaf—
were able to enhance Ras nanoclustering. We therefore
envisage that the basic mechanism driving an increase in
nanoclustering requires two RBDs in a Raf dimer that are
able to transiently crosslink Ras.GTP proteins. SFVT experi-
ments in live cells further show that Raf dimers increase the
actual rate of formation of Ras nanoclusters. We speculate
that the availability of crosslinking dimers at the time of
collision between Ras monomers increases the probability of
that collision leading to successful nanocluster assembly. In
this sense, the dimer may operate as an additional bivalent
nanocluster scaffold, similar to polyvalent galectin-3 that
facilitates assembly of K-Ras nanoclusters [18, 30–32]. Once
the Ras nanocluster has formed, the crosslinking activity of
the Raf dimer does not actually prolong the lifetime of the
resulting cluster.
Increasing the probability of nanocluster formation
increases the Ras clustered fraction and therefore promotes
MAPKactivation. This follows because the fraction of Ras.GTP
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Figure 6. Raf Inhibitors Enhance the Probability of K-RasG12V Cluster Formation
BHK cells were transfected with mGFP-KRasG12V and treated with DMSO, SB590885 (0.2 mM), or sorafenib (10 mM). The trajectories of single mGFP-K-
RasG12V molecules diffusing on the plasma membrane were tracked and analyzed.
(A) Representative trajectories of single K-RasG12Vmolecules that show periods of free diffusion and transient immobilization, which aremarked by circles.
(B) More than 750 individual trajectories were analyzed to generate distribution histograms of the duration and radii of all the temporary immobilization
events. The duration distributions were fitted by single exponential decay functions to provide the exponential time constants shown.
(C) A summary of the single-molecule imaging analysis of K-RasG12V. Differences between DMSO- and Raf inhibitor-treated cells were assessed using
Mann-Whitney U tests, and significant differences are indicated (**p < 0.01) (n, the number of occurrences of temporary immobilization events). The expo-
nential time constants derived in (B) were corrected for the photobleaching lifetime of mGFP on the cell surface (= 540 6 73 ms). The mean radii of immo-
bilization events derived in (B) were corrected for precision of localization as described in the Experimental Procedures. See also Movies S1, S2, and S3.
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952proteins that assemble into nanoclusters, the clustered
fraction, sets the gain for Ras-MAPK signal transmission
[3, 6–8, 23], therefore an increase in the Ras clustered fraction
will increase ppERK output at any given concentration of
Ras.GTP (Figure 7). The change in signal gain is most clearly
illustrated by the increased slope of the dose response to
EGF observed in BRaf inhibited cells (Figure 7). Our results
also account for the increased Raf translocation to the plasma
membrane seen in BRaf inhibited cells [12, 13, 15]; although
the total amount of Ras.GTP does not change in the presence
of Raf inhibitors, the number of Ras nanoclusters, which are
the sites for Raf recruitment to the plasma membrane, does
increase.
We observed an interesting interaction between Akt and
MAPK activity in cells treated with BRaf inhibitors; as MAPK
activity increased, pAkt levels decreased. Our results further
show that as Ras nanoclusters are crosslinked and occupied
by bivalent Raf complexes, p110a association with the plasma
membrane is inhibited. The simplest interpretation of these
data is that different effectors compete for recruitment to
Ras.GTP nanoclusters, such that if a Ras nanocluster is occu-
pied by a Raf, KSR, MEK, ERK complex, then access is denied
to PI3K. This phenomenon of effector exclusion is a novel form
of pathway crosstalk, not described previously [33], that could
contribute to the therapeutic effect of Raf inhibitors. Indeed,
we observed reciprocity between elevated ppERK and
decreased pAkt in a cohort of K-Ras transformed cancer cell
lines treated with BRaf inhibitors. Intriguingly, a recent study
has shown that other ATP-competitive kinase inhibitors,such as imatinib, nilotinib, and dasatinib, can also drive Raf
dimerization and drive paradoxical activation of MAPK in Ras
transformed cells [34]. It seems probable that the mechanism
for the effect of imatinib and these other weak Raf inhibitors
will be the same aswe have described here for BRaf inhibitors.
The weaker effect of Raf inhibitors on H-Ras.GTP nanoclus-
ters is an important result that merits further consideration.
The differential sensitivity of H-Ras.GTP and K-Ras.GTP nano-
clusters crosslinking by stabilized Raf dimers may in part be
explained by earlier work showing that whereas K-Ras.GTP
nanoclusters efficiently retain Raf recruited from the cytosol,
H-Ras.GTP nanoclusters do not [18]. However, the FLIM-
FRET results infer that Raf dimers are present in H-Ras.GTP
nanoclusters and in turn significantly abrogate PI3K/Akt
activation. Raf dimers are, however, unable to enhance
H-Ras nanoclustering. The molecular mechanism that under-
lies H-Ras nanoclustering is quite different from that for
K-Ras, and although a molecular scaffold, galectin-1, is
involved, this does not operate by crosslinking H-Ras.GTP
molecules but by stabilizing a conformation of H-Ras.GTP
that is favorable for nanocluster assembly [35–37]. Whatever
the reason for the failure of the dimers to enhance HG12V
nanoclustering, the inability to increase the H-Ras clustered
fraction can account for the much weaker activation of
MAPK in H-Ras transformed cells treated with BRaf inhibitors.
The spatiotemporal organization of Ras on the plasma
membrane endows important emergent properties on signal
transmission via theMAPK cascade.We show here that dysre-
gulation of the dynamics of nanocluster assembly is a major
Figure 7. Model of the Effect of BRaf Inhibitors on Ras Spatiotemporal
Dynamics
(A) A fixed proportion of K-Ras.GTP molecules (the clustered fraction)
assemble into transient signaling nanoclusters (blue circles). BRaf inhibition
generates stable Raf dimers that crosslink K-Ras.GTP (or N-Ras.GTP) mole-
cules facilitating nanocluster formation (red circles).
(B) Nanoclusters output fixed quanta of ppERK and total ppERK system
response is therefore the aggregated output from all signaling nanoclusters.
The consequences of Raf dimers facilitating nanocluster formation are to
increase the Ras clustered fraction (f) such that a greater number of nano-
clusters are assembled at any given Ras.GTP concentration. In turn, the
increased number of Ras nanoclusters generates a greater aggregated
ppERK output from the plasma membrane at each Ras.GTP concentration.
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953consequence of treating cells with BRaf inhibitors that results
in divergent consequences for MAPK and PI3K activity. The
study identifies perturbation of Ras spatiotemporal dynamics
as the molecular mechanism driving paradoxical activation
of the MAPK cascade by BRaf inhibitors, but also suggests
that these same dynamics may represent a novel target for
future therapeutic intervention.
Experimental Procedures
Cell Culture
Baby hamster kidney (BHK) cells were maintained in Dulbecco’s modified
Eagle medium (DMEM) (GIBCO) supplemented with 10% donor calf serum
(DCS). Chinese hamster ovarian cells (CHO) and A549 cells were maintained
in Ham’s F-12K medium (ATCC) supplemented with 10% fetal bovine serum
(FBS). HES and MDA-MB-231 cells were maintained in DMEM (GIBCO)
supplemented with 10% FBS. HEC-1a, Ishikawa, and ESS-1 cells were
maintained in McCoy’s 5A (GIBCO), MEM (GIBCO), and RPMI-1640
(ATCC), respectively, supplemented with 10% FBS. All cell lines were grown
at 37C in 5% CO2. To generate stable cell lines, we transfected BHK cells
with mGFP-RasG12V constructs in the pEF6/V5-His-Topo plasmid (Invitro-
gen) using Lipofectamine (Invitrogen) according to the manufacturer’s
instructions. Following an overnight incubation, GFP-Ras expressing cells
were isolated using fluorescence-activated cell sorting (FACS) and main-
tained in BHK medium containing 20 mg/mL blasticidin (Sigma Aldrich).
Fluorescence Lifetime Imaging-Fluorescence Resonance Energy
Transfer Microscopy
FLIM-FRET experiments were carried out using a lifetime fluorescence
imaging attachment (Lambert Instruments, The Netherlands) on an inverted
microscope [18]. BHK cells transiently expressing mGFP-tagged protein
(donor), alone or with mRFP-tagged protein (acceptor) (using a 1:1 ratio of
plasmid DNA), were prepared as indicated in each experiment. The samples
were excited using a sinusoidally modulated 3 W 470 nm light-emittingdiode at 40 MHz under epi-illumination. Fluorescein was used as a lifetime
reference standard. Cells were imagedwith a Plan Apo 60X 1.40 oil objective
using an appropriate GFP filter set. The phase and modulation were
determined from 12 phase settings using the manufacturer’s software.
Resolution of two lifetimes in the frequency domain was performed using
a graphical method [38] mathematically identical to global analysis algo-
rithms [39, 40]. The analysis yields the mGFP lifetime of free mGFP donor
(=t1), the mGFP lifetime in donor acceptor complexes (=t2), and estimates
the fraction of mGFP in donor-acceptor complexes (a). FRET efficiency is
then calculated as 1 2 t2/t1. FLIM data were averaged on a per-cell basis.
To quantify the fraction of mRFP without a functional chromophore, we per-
formed FLIM measurements on BHK cells expressing an mGFP-mRFP
fusion protein and obtained a value of a = 0.35 6 0.05 (mean 6 SEM). Our
estimates of FRET fractions take this into account.
EM and Spatial Mapping
Plasma membrane sheets were fixed and labeled with anti-GFP antibody
conjugated to 5 nm gold particles as previously described [41, 42]. For
bivariate analysis, plasma membrane sheets were labeled with anti-mRFP
antibody conjugated to 2 nm gold particles and anti-GFP antibody conju-
gated to 6 nm gold particles. Digital images of the immunogold-labeled
plasma membrane sheets were taken in a transmission electron micro-
scope. Intact 1 mm2 areas of the plasma membrane sheet were identified
using ImageJ, and the (x, y) coordinates of the gold particles were deter-
mined [41, 42]. K-functions [43] were calculated and standardized on the
99% or 95% confidence interval (C.I.) for univariate or bivariate functions,
respectively [41, 42, 44]. Bootstrap tests to examine differences between
replicated point patterns were constructed exactly as described previously
[8, 44], and statistical significance was evaluated against 1,000 bootstrap
samples. Extraction of clustered fractions and estimated number of gold
particles per cluster were extracted from the spatial point patterns as
previously described [8, 44]. Conversion of numbers of gold particles per
cluster to estimated number of Ras proteins per cluster used the measured
capture ratio of the anti-GFP antibody [8, 44].
Western Blotting
Cells were washed in cold phosphate-buffered saline (PBS) and subjected
to detergent lysis in a buffer containing 50 mM TrisCl (pH 7.5), 75 mM
NaCl, 25 mM NaF, 5 mM MgCl2, 5 mM EGTA, 1 mM dithiothreitol, 100 mM
NaVO4, and 1% Nonidet P40 plus protease inhibitors. SDS-PAGE and
immunoblotting with the specified antibody were performed using 20 mg
of each lysate. Signal was detected by enhanced chemiluminescence
(SuperSignal; Pierce, Thermo Fisher Scientific, Rockford, IL) and imaged
using a FluorChemQ (Alpha Inotech, San Leandro, CA). Quantification of
intensities was performed using FluorChemQ software.
Statistical Analysis
Prism (Version 5.0c, GraphPad Software) was used for one-way ANOVA
testing.
Video Tracking
SFVT was performed on BHK cells transiently expressing mGFP-
KRasG12V, as described previously [27]. To analyze and identify temporary
immobilization periods (TIMPs) of mGFP-KRasG12V, we used the method
developed by Sahl et al. [45]. The parameters used for the present analysis
were as follows: detection diameter 120 nm; threshold for detection = 3
frames; smoothing = 2 frames. We were unable to directly obtain the distri-
butions of the durations for diffusing events from the experiments because
the trajectory lengths (determined by photobleaching) were generally too
short to include two immobilization events and thus measure the duration
of diffusion. However, by assuming a simple exponential distribution of
mobile periods (as we observed for the TIMPs), we calculated the lifetime
for diffusing periods from the time fraction and the exponential lifetime of
the temporary immobilization. If:
½M= time fraction of the mobile period;
½I= time fraction of the immobile period
tM =exponential lifetime of the mobile period
tI = exponential lifetime of the immobile period
then :
½M
tM
=
½I
tI
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The size of an immobilized site was obtained as the SD of the distance
between the average position during the immobilization period and the
position determined for each image frame (during immobilization). This
value was corrected for the precision of localization (determination of the
position of single molecules), which was convoluted in the experimental
measurements. The localization error (Gaussian) was 19.8 (60.48) nm. The
radius after subtracting localization error was obtained by the following
equation:
h
ðestimated radiusÞ22 ð19:8Þ2
i1=2
To determine the localization error for mGFP, we attached mGFP to and
immobilized it on a coverslip. From the determined coordinates of single
molecules, the distance between the determined positions in consecutive
frames (= the step size) was calculated for all the obtained trajectories.
The distribution of the step size x (in the x direction) was obtained and fitted
by the following equation:
fðXÞ= X
2s2mGFP
exp

2
X2
4s2mGFP

where smGFP is the fitting parameter, giving the localization error. The
error for this distribution can be estimated by the fitting error for the
68.3% confidence limit, which was 0.47 nm.
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Supplemental Information includes four figures, one table, and threemovies
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